Literature DB >> 9049861

Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas.

M J Pykett1, J Landers, D L George.   

Abstract

Meningiomas represent a common class of tumors of the central nervous system. However, the molecular events underlying their formation are poorly understood. Because altered expression of the p53 tumor suppressor gene and the mdm2 proto-oncogene have been demonstrated in a wide variety of tumors, we carried out studies to assess the possible involvement of these two genes in meningioma tumorigenesis. We used Western blot analysis to examine the level of expression of the mdm2 and p53 proteins in a series of sixteen primary meningiomas and four meningioma cell lines. The data obtained from these studies suggest that elevated expression of the p53 or mdm2 protein products does not represent a common event in the development of human meningiomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049861     DOI: 10.1023/a:1005779406636

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  40 in total

1.  Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line.

Authors:  L Cahilly-Snyder; T Yang-Feng; U Francke; D L George
Journal:  Somat Cell Mol Genet       Date:  1987-05

Review 2.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

3.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

4.  Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.

Authors:  M H Ruttledge; J Sarrazin; S Rangaratnam; C M Phelan; E Twist; P Merel; O Delattre; G Thomas; M Nordenskjöld; V P Collins
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

5.  p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

Authors:  F S Leach; T Tokino; P Meltzer; M Burrell; J D Oliner; S Smith; D E Hill; D Sidransky; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

6.  p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.

Authors:  D Fults; D Brockmeyer; M W Tullous; C A Pedone; R M Cawthon
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

7.  MDM2 gene amplification in metastatic osteosarcoma.

Authors:  M Ladanyi; C Cha; R Lewis; S C Jhanwar; A G Huvos; J H Healey
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

8.  Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.

Authors:  R H Lekanne Deprez; A B Bianchi; N A Groen; B R Seizinger; A Hagemeijer; E van Drunen; D Bootsma; J W Koper; C J Avezaat; N Kley
Journal:  Am J Hum Genet       Date:  1994-06       Impact factor: 11.025

9.  Identification of a microsatellite instability phenotype in meningiomas.

Authors:  M J Pykett; M Murphy; P R Harnish; D L George
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

10.  TP53 allele loss, mutations and expression in malignant melanoma.

Authors:  V A Flørenes; T Oyjord; R Holm; M Skrede; A L Børresen; J M Nesland; O Fodstad
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

View more
  7 in total

1.  Loss of heterozygosity on chromosome 22q and 17p correlates with aggressiveness of meningiomas.

Authors:  J H Kim; S H Lee; C H Rhee; S Y Park; J H Lee
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

2.  Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.

Authors:  Michel Kalamarides; Michiko Niwa-Kawakita; Hélène Leblois; Vincent Abramowski; Michel Perricaudet; Anne Janin; Gilles Thomas; David H Gutmann; Marco Giovannini
Journal:  Genes Dev       Date:  2002-05-01       Impact factor: 11.361

3.  Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression.

Authors:  R G Weber; J Boström; M Wolter; M Baudis; V P Collins; G Reifenberger; P Lichter
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

4.  Loss of heterozygosity at 1p, 7q, 17p, and 22q in meningiomas.

Authors:  In Bok Chang; Byung Moon Cho; Seung Myung Moon; Se Hyuck Park; Sae Moon Oh; Seong Jin Cho
Journal:  J Korean Neurosurg Soc       Date:  2010-07-31

5.  Loss of p53 expression is accompanied by upregulation of beta-catenin in meningiomas: a concomitant reciprocal expression.

Authors:  Nives Pećina-Šlaus; Anja Kafka; Tomislav Vladušić; Davor Tomas; Monika Logara; Josip Skoko; Reno Hrašćan
Journal:  Int J Exp Pathol       Date:  2016-06-12       Impact factor: 1.925

6.  A role for the p53 pathway in the pathology of meningiomas with NF2 loss.

Authors:  ZeNan Chang; Chin-Lin Guo; Iris Ahronowitz; Anat O Stemmer-Rachamimov; Mia MacCollin; Fabio P Nunes
Journal:  J Neurooncol       Date:  2008-11-01       Impact factor: 4.130

7.  Nucleotide variations of TP53 exon 4 found in intracranial meningioma and in silico prediction of their significance.

Authors:  Anja Bukovac; Anja Kafka; Reno Hrašćan; Tomislav Vladušić; Nives Pećina-Šlaus
Journal:  Mol Clin Oncol       Date:  2019-10-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.